How to Choose a Sterile Fill-Finish CDMO: 7 Questions Every CMC Team Should Ask

When selecting a sterile fill-finish Contract Development and Manufacturing Organisation (CDMO), the most consequential evaluation criteria are regulatory compliance history, aseptic process technology, lyophilisation capability, clinical-to-commercial scalability, network redundancy, technology transfer rigour and quality governance. Asking these seven questions before entering into a master service agreement will significantly reduce programme risk and ensure your outsourcing partner is aligned with the long-term needs of your asset.

Sterile fill-finish is one of the most technically demanding and regulatory-sensitive processes in pharmaceutical manufacturing. A single inspection observation, an equipment limitation or a misaligned quality culture can delay a product launch by months or, in extreme cases, compromise patient supply entirely. The decision is not simply one of cost or capacity; it is a strategic commitment that will shape the trajectory of your programme from Phase I clinical supply through to global commercial distribution.

The questions below are designed to structure your due diligence process. They are applicable whether you are evaluating a partner for a biologics candidate, a controlled substance or a small molecule injectable. Each question is paired with the rationale behind it and the indicators that distinguish a credible answer from a rehearsed one.

Question 1: What Is the CDMO’s Regulatory Track Record Across Multiple Health Authorities?

A sterile fill-finish CDMO should be able to demonstrate a sustained history of successful inspections by recognised regulatory bodies, including the European Medicines Agency, the United States Food and Drug Administration and, where relevant, national competent authorities such as Swissmedic in Switzerland or the Pharmaceuticals and Medical Devices Agency in Japan.

Ask specifically for the date of the most recent inspection by each authority, the classification of any observations received and the documented corrective and preventive actions taken in response. A partner holding current approvals from twelve or more international health authorities provides meaningful assurance that its quality systems have withstood rigorous external scrutiny across diverse regulatory frameworks. This scope of certification is particularly relevant for products with a global commercial strategy that spans European, North American and Asian markets simultaneously.

Do not limit this line of enquiry to European approvals. If your commercial strategy includes the United States, Japan or other regulated markets, verify that your CDMO holds the relevant authority certifications for the specific facility and filling line proposed for your product, not simply the organisation as a whole. The FDA guidance on sterile drug products produced by aseptic processing sets out the baseline standards a commercially operating sterile site must meet and is a useful reference for framing your inspection readiness questions.

Question 2: What Aseptic Fill Technology Does the CDMO Operate, and Is It Appropriate for Your Product?

The two primary aseptic processing environments used in sterile fill-finish manufacturing are Restricted Access Barrier Systems (RABS) and isolators. Both technologies are designed to protect the product from microbial contamination during filling, but they differ in containment level, operational flexibility and suitability for different product types and risk profiles.

Restricted Access Barrier Systems are widely used for high-speed commercial filling and offer a practical balance between operator access and contamination control. Isolators provide a higher degree of physical separation between operators and the product and are typically selected for highly potent compounds or products with enhanced containment requirements. When evaluating a CDMO, ask which technology is installed on the specific line proposed for your programme and whether full Aseptic Process Simulation (APS) data for that line is available for review.

Verifying the age and qualification status of the equipment is equally important. The revised EMA Annex 1 on the Manufacture of Sterile Medicinal Products sets detailed expectations for contamination control strategies and barrier technology. Equipment that has not been maintained to current Good Manufacturing Practice (GMP) standards represents a regulatory liability regardless of how capable the operator team may be. Confirm also that the line holds a current, fully compliant APS, as this is the primary demonstration that the aseptic process can maintain sterility under simulated production conditions.

Question 3: Does the CDMO Offer Lyophilisation Capability, and at What Scale?

Lyophilisation, commonly referred to as freeze-drying, is required for a significant proportion of biological drug products and small molecule injectables that are thermally labile or require extended shelf life in a reconstitutable format. Not all fill-finish CDMOs offer lyophilisation capability, and those that do vary considerably in shelf area, batch capacity, equipment age and the level of process development support available.

Ask for the total lyophiliser shelf area across all available units, the maximum number of vials that can be processed per batch, the qualification and validation status of each lyophiliser and whether the CDMO can support lyophilisation cycle development as part of the engagement or whether that must be conducted elsewhere prior to technology transfer.

For clinical-stage programmes in particular, the ability to manufacture at varied batch sizes without being constrained by a minimum batch commitment is a practical and financial consideration. A facility capable of processing up to 74,000 vials per batch with no minimum batch size restriction provides the flexibility that early-phase programmes require, whilst ensuring that the same infrastructure can sustain volume as the programme advances. Confirm that the CDMO’s lyophilisation capacity spans the range relevant to your anticipated programme needs, from early-phase clinical batches through to commercial-scale production, and that scale-up does not necessitate a move to a different site or a different lyophiliser configuration.

Question 4: Can the CDMO Support a Seamless Transition from Clinical to Commercial Manufacturing?

The regulatory, operational and financial costs of transferring a product between CDMOs at the point of commercialisation are substantial. A sponsor that moves from a clinical-stage contract manufacturer to a separate commercial-scale manufacturer must repeat elements of process validation, analytical method transfer and regulatory filing, which introduces time and risk at a stage of the programme when both are least affordable.

Wherever it is feasible, a partner that can support your programme from early-phase clinical supply through to high-volume commercial production provides continuity of process knowledge, reduces the regulatory documentation burden and simplifies supply chain governance. When evaluating this capability, ask whether the CDMO has dedicated clinical and commercial filling lines, whether they have executed successful scale-up programmes within their own network and whether they can provide references or data from comparable programmes.

Understand clearly whether the commercial line proposed for your product is within the same facility as the clinical line or at a separate site, and what that implies for technology transfer activity and timelines. A three-month turnaround from order to first Good Manufacturing Practice batch, applicable across both clinical and commercial programmes, is a meaningful benchmark for evaluating a partner’s responsiveness and infrastructure readiness. Five or more successful commercial launches from within a single clinical fill-finish network is a further indicator that the pathway from development to commercial supply has been demonstrated in practice, not merely described in a capability statement.

Question 5: Does the CDMO Operate a Multi-Site Network Capable of Providing Supply Redundancy?

Single-site dependency is a documented and well-understood risk in pharmaceutical supply chains. Regulatory observations, equipment failure or unforeseeable operational disruptions at a single facility can interrupt patient supply with consequences that are both commercially significant and, in some therapeutic areas, clinically serious.

A CDMO that operates an integrated multi-site sterile manufacturing network provides a structural layer of resilience that a single-site provider cannot replicate. This is not simply a commercial advantage; for products that are critical to patient care, supply continuity is an ethical and regulatory obligation. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH Q10) pharmaceutical quality system guidelines explicitly address the importance of supply chain resilience and continuity planning at the organisational level.

When assessing network capability, ask whether more than one facility within the CDMO’s network is capable of manufacturing your specific product format and container type. Ask whether the CDMO has a documented business continuity protocol that covers site-level disruption and whether they have experience executing technology transfers between their own facilities. This operational capability is what makes network redundancy meaningful rather than theoretical. A network spanning Switzerland, France and Japan, with distinct but complementary filling capabilities at each site, provides a qualitatively different level of supply assurance than a multi-building arrangement within a single campus.

Question 6: What Does the CDMO’s Technology Transfer Process Look Like, and Who Leads It?

Technology transfer is the stage at which many CDMO partnerships either establish a strong foundation or begin to show signs of strain. The process involves moving analytical methods, formulation knowledge, manufacturing process parameters and regulatory documentation from the sponsor or a previous manufacturer into the CDMO’s quality management system. A poorly structured transfer can introduce process variability, delay Good Manufacturing Practice batch release and generate regulatory queries at critical programme milestones.

Ask who leads the technology transfer on the CDMO’s side. A named and experienced project manager with a single, consistent point of contact throughout the engagement, rather than a rotating team, is a positive indicator of how the partner structures accountability. Understand what documentation is required from the sponsor prior to initiation, what the CDMO’s standard stage gates are from feasibility through to first Good Manufacturing Practice batch and what the escalation pathway is when a technical issue arises during transfer.

The quality of a CDMO’s project management infrastructure is often best assessed by asking for a sample project timeline or a description of how a previous transfer was managed when an unexpected challenge arose. The candour and specificity of the response will tell you more than any written capability statement. Seek also to understand whether the CDMO’s project management extends to secondary packaging, clinical kit preparation and temperature-controlled distribution, as these downstream steps are frequently underestimated in early programme planning.

Question 7: How Is Quality Governance Structured, and What Are the Escalation Protocols?

Quality governance in a fill-finish CDMO is not measured solely by the volume of standard operating procedures in its document management system. It encompasses the accountability structures, the responsiveness of the quality organisation and the culture that determines how deviations are identified, communicated and resolved.

Ask what the CDMO’s average deviation closure time is and how Out-of-Specification results are escalated to sponsor teams. Ask whether the Quality Director is accessible to client contacts or whether quality interactions are filtered through a commercial layer. Ask how findings from regulatory authority inspections are communicated to existing clients and how change controls affecting your product are managed. These are not adversarial questions; they are the questions that a mature quality organisation will welcome.

Seek independent indicators of quality maturity. A facility that regularly accommodates twelve or more client quality audits per year demonstrates a level of openness and procedural confidence that is difficult to sustain without robust underlying quality systems. This level of audit throughput also indicates that the facility has the infrastructure and documentation discipline to support multiple concurrent client programmes without quality resources becoming a bottleneck. This is a meaningful signal in a sector where quality culture is often the determining factor in long-term partnership success.

Frequently Asked Questions

What is the difference between RABS and isolator technology in sterile fill-finish manufacturing?

Restricted Access Barrier Systems (RABS) are physical barrier systems installed around filling equipment to limit operator access to the critical zone, reducing the risk of microbial contamination during aseptic filling operations. Isolators are fully enclosed, pressure-controlled environments that provide a higher degree of physical separation between the operator and the product. Isolators are typically selected for highly potent active pharmaceutical ingredients or products with specific containment requirements. Restricted Access Barrier Systems offer a high level of contamination control while maintaining operational flexibility and are well-suited to a broad range of injectable product types, including prefilled syringes and lyophilised and liquid vials at both clinical and commercial scale.

How many regulatory authority approvals should a sterile fill-finish CDMO hold?

There is no universal minimum that applies across all programmes, but a credible commercial-scale fill-finish CDMO should hold current approvals from at least the European Medicines Agency and, where you intend to supply the United States, the United States Food and Drug Administration. Swiss sites should additionally hold Swissmedic certification. National approvals from authorities in Japan, Brazil, South Korea, China and comparable markets become relevant where your commercial distribution strategy extends into those territories. The scope of regulatory approvals held by a facility should align directly with the geographic reach of your distribution strategy, and certification at the level of the specific filling line, not simply the organisation, is what matters for regulatory submissions.

What is a realistic technology transfer timeline for sterile fill-finish manufacturing?

Timelines vary depending on product complexity, the completeness of the technical package provided by the sponsor and the CDMO’s existing familiarity with comparable formulations and processes. For straightforward liquid vial products transferring into a CDMO with established process knowledge, a timeline of three to six months from project initiation to first Good Manufacturing Practice batch is achievable in well-managed programmes. Lyophilised products, products with novel formulation characteristics or those requiring controlled substance authorisations typically require longer timelines. These should be discussed and documented in detail during the feasibility phase of any engagement, with stage-gated milestones clearly defined and agreed in writing before manufacturing activities commence.

Can a single CDMO handle both small molecule injectables and biological drug products?

Yes, provided the CDMO holds the appropriate equipment qualifications, validated cleaning and changeover procedures and regulatory approvals covering both product categories. Not all fill-finish CDMOs have the equipment or regulatory authorisation for biological products, which may require cold chain formulation conditions, specialised containment and enhanced environmental monitoring protocols. When evaluating a potential partner, request confirmation of which product categories are represented in their existing client portfolio and ask for evidence that their equipment qualification covers the specific requirements of your molecule class. The CDMO should be able to demonstrate prior experience with biologics, not simply assert that their equipment is capable of it.

What does no minimum batch size mean in the context of clinical trial material manufacturing?

Some CDMOs impose minimum batch size requirements to ensure the commercial viability of each production run within their operations. A CDMO that operates without a minimum batch size commitment allows sponsors to manufacture the precise quantity of material required for a given clinical study, which is of particular value in early-phase development where patient numbers are limited and Active Pharmaceutical Ingredient availability may be constrained. This approach reduces material waste, controls programme cost and allows clinical development to advance at the pace dictated by the study design rather than by manufacturing volume thresholds. It is particularly relevant for high-value molecules where the cost of excess material represents a material risk to the development budget.

How do I choose between a specialist clinical CDMO and a full-service sterile CDMO?

The primary consideration is whether you expect your product to require a transfer to a different manufacturer at the point of commercial launch. Specialist clinical CDMOs typically offer flexibility, small batch sizes and rapid turnaround, but may not have the high-speed commercial filling lines, automated inspection capacity or regulatory authority certifications required for large-scale commercial supply. A full-service sterile CDMO with both clinical and commercial capabilities within the same network allows you to advance through development phases without repeating validation or regulatory filings at the point of commercialisation. Where the clinical and commercial infrastructure sits within a single integrated network, the continuity of process knowledge also reduces the risk of introducing variability during scale-up.